Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 510-515

  Almasi, Charlotte Elberling ^a   Christensen, Ib Jarle ^a   Høyer Hansen, Gunilla ^a   Danø, Keld ^a   Pappot, Helle ^a,b   Dienemann, Hendrik ^c   Muley, Thomas ^c  

^a FINSEN LABORATORY   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cleaved uPAR; Non small cell lung carcinoma; Prognosis; Time resolved fluorescence immunoassays; UPAR; Urokinase plasminogen activator receptor

Indexed keywords

UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; FEMALE; FLUORESCENCE ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SERUM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; PROGNOSIS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 80755190010     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.05.008     Document Type: Article

References (36)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. American Cancer Society ISR Cancer Facts & Figures 2007.
4. Azzoli C.G., Park B.J., Pao W., Zakowski M., Kris M.G. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. J Thorac Oncol 2008, 3:84-93.
5. Sculier J.P., Chansky K., Crowley J.J., Van M.J., Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008, 3:457-466.
6. Vielh P., Spano J.P., Grenier J., Le C.T., Soria J.C. Molecular prognostic factors in resectable non-small cell lung cancer. Crit Rev Oncol Hematol 2005, 53:193-197.
7. Andreasen P.A., Egelund R., Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000, 57:25-40.
8. Danø K., Behrendt N., Høyer-Hansen G., Johnsen M., Lund L.R., Ploug M., et al. Plasminogen activation and cancer. Thromb Haemost 2005, 93:676-681.
9. Høyer-Hansen G., Lund I.K. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007, 44:65-102.
10. Pappot H., Høyer-Hansen G., Rønne E., Hansen H.H., Brunner N., Danø K., et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997, 33:867-872.
11. Ganesh S., Sier C.F., Heerding M.M., Griffioen G., Lamers C.B., Verspaget H.W. Urokinase receptor and colorectal cancer survival. Lancet 1994, 344:401-402.
12. Grøndahl-Hansen J., Peters H.A., van Putten W.L., Look M.P., Pappot H., Rønne E., et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995, 1:1079-1087.
13. Pedersen H., Brünner N., Francis D., Østerlind K., Rønne E., Hansen H.H., et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994, 54:4671-4675.
14. Riisbro R., Christensen I.J., Piironen T., Greenall M., Larsen B., Stephens R.W., et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002, 8:1132-1141.
15. Shariat S.F., Roehrborn C.G., McConnell J.D., Park S., Alam N., Wheeler T.M., et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007, 25:349-355.
16. Stephens R.W., Nielsen H.J., Christensen I.J., Thorlacius-Ussing O., Sørensen S., Danø K., et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999, 91:869-874.
17. Behrendt N., Rønne E., Danø K. Domain interplay in the urokinase receptor Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem 1996, 271:22885-22894.
18. Høyer-Hansen G., Behrendt N., Ploug M., Danø K., Preissner K.T. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 1997, 420:79-85.
19. Høyer-Hansen G., Rønne E., Solberg H., Behrendt N., Ploug M., Lund L.R., et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992, 267:18224-18229.
20. Høyer-Hansen G., Ploug M., Behrendt N., Rønne E., Danø K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997, 243:21-26.
21. Almasi C.E., Høyer-Hansen G., Christensen I.J., Danø K., Pappot H. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 2005, 48:349-355.
22. Almasi C.E., Høyer-Hansen G., Christensen I.J., Pappot H. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. APMIS 2009, 117:755-761.
23. Travis W.D., Colby T.V., Shimosato Y., Brambilla E. Histological typing of lung and pleural tumors: WHO International Histological Classification of Tumours 1999, Springer, Berlin, Germany. 3rd ed.
24. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717.
25. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
26. Piironen T., Laursen B., Pass J., List K., Gårdsvoll H., Ploug M., et al. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 2004, 50:2059-2068.
27. Pappot H. The plasminogen activation system in lung cancer-with special reference to the prognostic role in " non-small cell lung cancer" APMIS Suppl 1999, 92:1-29.
28. Plesner T., Ploug M., Ellis V., Ronne E., Hoyer-Hansen G., Wittrup M., et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 1994, 83:808-815.
29. Jung K., Lein M., Laube C., Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001, 314:241-244.
30. Jung K. Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood. Arterioscler Thromb Vasc Biol 2008, 28:e15-e16.
31. Muley T., Fetz T.H., Dienemann H., Hoffmann H., Herth F.J., Meister M., et al. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer 2008, 60:408-415.
32. Pujol J.L., Molinier O., Ebert W., Daures J.P., Barlesi F., Buccheri G., et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004, 90:2097-2105.
33. Almasi C.E., Brasso K., Iversen P., Pappot H., Høyer-Hansen G., Danø K., et al. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate 2011, 71:899-907.
34. Piironen T., Haese A., Huland H., Steuber T., Christensen I.J., Brünner N., et al. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 2006, 52:838-844.
35. Henic E., Borgfeldt C., Christensen I.J., Casslen B., Hoyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008, 14:5785-5793.
36. Bach P.B. Is our natural-history model of lung cancer wrong?. Lancet Oncol 2008, 9:693-697.